AU2002218306A1 - Von willebrand factor (vWF) cleaving protease polypeptide, nucleic acid encoding the polypeptide and use of polypeptide - Google Patents

Von willebrand factor (vWF) cleaving protease polypeptide, nucleic acid encoding the polypeptide and use of polypeptide

Info

Publication number
AU2002218306A1
AU2002218306A1 AU2002218306A AU1830602A AU2002218306A1 AU 2002218306 A1 AU2002218306 A1 AU 2002218306A1 AU 2002218306 A AU2002218306 A AU 2002218306A AU 1830602 A AU1830602 A AU 1830602A AU 2002218306 A1 AU2002218306 A1 AU 2002218306A1
Authority
AU
Australia
Prior art keywords
vwf
polypeptide
seq
acid sequence
amino acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2002218306A
Other languages
English (en)
Inventor
Gerhard Antoine
Miha Furlan
Randolf Kerschbaumer
Bernhard Laemmle
Helena Schaller-Gerritsen
Friedrich Scheiflinger
Doz. Hans-Peter Schwarz
Luigina Tagliavacca
Peter Turecek
Dirk Voelkel
Klaus Zimmermann
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Baxter AG
Original Assignee
Baxter AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27110398&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AU2002218306(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Baxter AG filed Critical Baxter AG
Publication of AU2002218306A1 publication Critical patent/AU2002218306A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/4886—Metalloendopeptidases (3.4.24), e.g. collagenase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745—Blood coagulation or fibrinolysis factors
    • C07K14/755—Factors VIII, e.g. factor VIII C (AHF), factor VIII Ag (VWF)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/36—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against blood coagulation factors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6402—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from non-mammals
    • C12N9/6405—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from non-mammals not being snakes
    • C12N9/6416—Metalloendopeptidases (3.4.24)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6489—Metalloendopeptidases (3.4.24)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/24—Metalloendopeptidases (3.4.24)
    • C12Y304/24087—ADAMTS13 endopeptidase (3.4.24.87)

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hematology (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Toxicology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Diabetes (AREA)
  • Peptides Or Proteins (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Chemical Or Physical Treatment Of Fibers (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
AU2002218306A 2000-11-22 2001-11-20 Von willebrand factor (vWF) cleaving protease polypeptide, nucleic acid encoding the polypeptide and use of polypeptide Abandoned AU2002218306A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US72125400A 2000-11-22 2000-11-22
US09721254 2000-11-22
US09833328 2001-04-12
US09/833,328 US6926894B2 (en) 2000-11-22 2001-04-12 Composition exhibiting a von willebrand factor (vWF) protease activity comprising a polypeptide chain with the amino acid sequence AAGGILHLELLV
PCT/EP2001/013391 WO2002042441A2 (en) 2000-11-22 2001-11-20 VON WILLEBRAND FACTOR (vWF) CLEAVING PROTEASE POLYPEPTIDE, NUCLEIC ACID ENCODING THE POLYPEPTIDE AND USE OF POLYPEPTIDE

Publications (1)

Publication Number Publication Date
AU2002218306A1 true AU2002218306A1 (en) 2002-06-03

Family

ID=27110398

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2002218306A Abandoned AU2002218306A1 (en) 2000-11-22 2001-11-20 Von willebrand factor (vWF) cleaving protease polypeptide, nucleic acid encoding the polypeptide and use of polypeptide

Country Status (15)

Country Link
US (7) US6926894B2 (da)
EP (1) EP1346034B1 (da)
AT (1) ATE423194T1 (da)
AU (1) AU2002218306A1 (da)
CZ (1) CZ305602B6 (da)
DE (1) DE60137710D1 (da)
DK (1) DK1346034T3 (da)
ES (1) ES2322126T3 (da)
HU (1) HU227996B1 (da)
NZ (1) NZ526616A (da)
PT (1) PT1346034E (da)
RU (1) RU2003118441A (da)
SI (1) SI1346034T1 (da)
SK (1) SK288119B6 (da)
WO (1) WO2002042441A2 (da)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6926894B2 (en) 2000-11-22 2005-08-09 Baxter Aktiengesellschaft Composition exhibiting a von willebrand factor (vWF) protease activity comprising a polypeptide chain with the amino acid sequence AAGGILHLELLV
JP2003284570A (ja) * 2001-04-25 2003-10-07 Chemo Sero Therapeut Res Inst フォンビルブラント因子（ｖＷＦ）切断酵素
AU2002336367A1 (en) * 2001-08-16 2003-03-03 The Regents Of The University Of Michigan Adamts13 genes and proteins and variants, and uses thereof
DE20213920U1 (de) 2002-07-03 2003-01-16 Boehm Martina Diagnostikum zum Nachweis der den von Willebrand-Faktorspaltenden Aktivität von ADAMTS13
AU2012203101B2 (en) * 2002-09-25 2014-10-02 Km Biologics Co., Ltd. Antibody against enzyme specifically cleaving von villebrand factor and assay system using the same
KR101154550B1 (ko) * 2002-09-25 2012-06-08 잇판자이단호진 가가쿠오요비겟세이료호겐쿠쇼 폰 빌레브란트 인자 특이적 절단 효소에 대한 항체 및그것을 이용한 분석계
US20040185042A1 (en) * 2003-03-20 2004-09-23 Friedrich Scheiflinger Immunoadsorption of anti-von Willebrand Factor cleaving protease antibodies
US7763430B2 (en) * 2003-04-22 2010-07-27 Baxter International Inc. Diagnostic assay for anti-von Willebrand Factor cleaving protease (ADAMTS13) antibodies
JP4621593B2 (ja) * 2003-12-22 2011-01-26 三菱化学メディエンス株式会社 フォンヴィルブランド因子分解酵素の測定による血栓症の検出方法
EP1568782A1 (de) * 2004-02-25 2005-08-31 Clemens Bockmeyer Diagnose und Therapie von ADAMTS-13 assoziierten Erkrankungen
US7270976B2 (en) * 2004-07-19 2007-09-18 American Diagnostica, Inc. Methods for measuring ADAMTS13 activity and protein on platelets and in plasma
DE602004027314D1 (de) * 2004-07-19 2010-07-01 American Diagnostica Inc Verfahren zur messung von adamts13-aktivität auf der blutplättchenoberfläche.
US20080138837A1 (en) * 2004-07-19 2008-06-12 Robert Greenfield Methods and kits for detecting and measuring ADAMTS13/FXI complexes
WO2006133955A1 (en) 2005-06-17 2006-12-21 Baxter International Inc. Adamts13-comprising compositions having thrombolytic activity
US7893616B2 (en) * 2006-02-27 2011-02-22 Ohio State University Process to determine enzyme activity
FR2918375B1 (fr) 2007-07-05 2009-10-16 Lab Francais Du Fractionnement Utilisation d'un support de chromatographie pour reduire la quantite d'adamts13 dans une solution derivee du plasma
SG10201503304RA (en) * 2007-12-27 2015-06-29 Baxter Int Cell culture processes
US8945895B2 (en) 2009-07-31 2015-02-03 Baxter International Inc. Methods of purifying recombinant ADAMTS13 and other proteins and compositions thereof
IN2012DN00801A (da) 2009-07-31 2015-06-26 Baxter Int
ES2948612T3 (es) 2009-09-21 2023-09-14 Takeda Pharmaceuticals Co Formulaciones de ADAMTS13 líquidas y liofilizadas estabilizadas
KR102007773B1 (ko) 2010-07-08 2019-08-06 박스알타 인코퍼레이티드 세포 배양에서 재조합 고분자량 ｖＷＦ를 생산하는 방법
WO2012082933A1 (en) 2010-12-15 2012-06-21 Baxter International, Inc. Eluate collection using conductivity gradient
US20120315650A1 (en) 2011-05-19 2012-12-13 Baxter International, Inc. Detection of circulating adamts13-antibody complexes
KR102006151B1 (ko) 2012-11-27 2019-10-10 삼성디스플레이 주식회사 터치를 인식하고 전기 촉각 자극을 제공하는 표시 장치 및 그 구동 방법
AU2013203062C1 (en) 2013-03-15 2018-06-28 Takeda Pharmaceutical Company Limited Subcutaneous administration of adamts13
WO2016186994A1 (en) * 2015-05-15 2016-11-24 Children's Medical Center Corporation Methods relating to the diagnosis and treatment of thrombotic microangiopathy
MX2019001255A (es) 2016-08-04 2019-05-20 Baxalta Inc Uso de una desintegrina y metaloproteinasa con motivo tipo 1 de trombospondina, miembro-13 (adamts13) para tratar, mejorar y/o prevenir crisis vaso-oclusiva en enfermedad de celulas falciformes, lesion pulmonar aguda y/o sindrome de insuficiencia respiratoria aguda.
FR3069156B1 (fr) * 2017-07-21 2019-08-09 Universite de Bordeaux Clusterine pour son utilisation dans le traitement des micro-angiopathies thrombotiques
BR112022019817A2 (pt) 2020-04-02 2022-12-06 Takeda Pharmaceuticals Co Variante de adamts13, composições e usos das mesmas
JP2023526546A (ja) 2020-05-22 2023-06-21 武田薬品工業株式会社 コロナウイルス疾患の合併症の治療及び診断のための、ａｄａｍｔｓ１３組成物及び方法

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6068838A (en) * 1996-04-29 2000-05-30 Baxter Aktiengesellschaft Purified multimerase
AT406867B (de) * 1997-02-27 2000-10-25 Immuno Ag Verfahren zur gewinnung von hochreinem vwf oder faktor viii/vwf-komplex
US20010049106A1 (en) * 2000-04-27 2001-12-06 Leonard Buckbinder ADAMTS polypeptides, nucleic acids encoding them, and uses thereof
US6926894B2 (en) * 2000-11-22 2005-08-09 Baxter Aktiengesellschaft Composition exhibiting a von willebrand factor (vWF) protease activity comprising a polypeptide chain with the amino acid sequence AAGGILHLELLV
US7070532B2 (en) * 2003-08-26 2006-07-04 General Motors Corporation Planetary transmission having a rotating-type torque-transmitting mechanism with a stationary piston

Also Published As

Publication number Publication date
US8703429B2 (en) 2014-04-22
US20090203110A1 (en) 2009-08-13
WO2002042441A2 (en) 2002-05-30
US9309506B2 (en) 2016-04-12
ATE423194T1 (de) 2009-03-15
EP1346034A2 (en) 2003-09-24
US20020136713A1 (en) 2002-09-26
HUP0400588A2 (hu) 2004-06-28
DE60137710D1 (de) 2009-04-02
US20140335071A1 (en) 2014-11-13
ES2322126T3 (es) 2009-06-17
SK8022003A3 (en) 2004-04-06
US7910094B2 (en) 2011-03-22
RU2003118441A (ru) 2004-12-10
DK1346034T3 (da) 2009-05-11
US20090017467A1 (en) 2009-01-15
US7501117B2 (en) 2009-03-10
WO2002042441A3 (en) 2002-08-08
US20050266528A1 (en) 2005-12-01
US8703426B2 (en) 2014-04-22
US20170065686A1 (en) 2017-03-09
EP1346034B1 (en) 2009-02-18
PT1346034E (pt) 2009-05-05
US20080176312A1 (en) 2008-07-24
HUP0400588A3 (en) 2006-01-30
SI1346034T1 (sl) 2009-08-31
HU227996B1 (hu) 2012-08-28
CZ305602B6 (cs) 2016-01-06
CZ20031718A3 (cs) 2004-07-14
US6926894B2 (en) 2005-08-09
NZ526616A (en) 2005-04-29
SK288119B6 (sk) 2013-09-03

Similar Documents

Publication Publication Date Title
EP1346034B1 (en) VON WILLEBRAND FACTOR (vWF) CLEAVING PROTEASE POLYPEPTIDE, NUCLEIC ACID ENCODING THE POLYPEPTIDE AND USE OF POLYPEPTIDE
AU699748B2 (en) Recombinant HK2 polypeptide
Hayashi et al. Protein S Tokushima: abnormal molecule with a substitution of Glu for Lys-155 in the second epidermal growth factor-like domain of protein S
US5043429A (en) Protein fragments containing Factor VIII binding domain of von Willebrand Factor
CA2104394A1 (en) Recombinant thrombin receptor and related pharmaceuticals
US7083940B2 (en) Pregnancy-associated plasma protein-A2 (PAPP-A2)
CA2252986C (en) Process for preparing functional recombinant tissue factor
BORGEL et al. Implication of protein S thrombin-sensitive region with membrane binding via conformational changes in the γ-carboxyglutamic acid-rich domain
JP2008532536A (ja) 新規の非タンパク分解起源の可溶性ｅｐｃｒタンパク質およびその使用
Malm et al. Expression of completely γ‐carboxylated and β‐hydroxylated recombinant human vitamin‐K‐dependent protein S with full biological activity
US5500344A (en) Serine protease and uses thereof
ZA200304741B (en) Von willebrand factor (vWF) cleaving protease polypeptide, nucleic acid encoding the polypeptide and use of polypeptide.
US7084113B2 (en) Protein having antithrombotic activity and method for producing the same
US20050043254A1 (en) Novel serine protease inhibitory protein mt0039
Drohan et al. Recombinant Technology in Hemostasis and Thrombosis